In Vivo Large Scale Mapping Of Protein Turnover In The Human Cerebrospinal Fluid

The extraction of accurate physiological parameters from clinical samples provides a unique perspective to understand disease etiology and evolution, including under therapy. We introduce a new proteomics framework to map patient proteome dynamics in vivo, either proteome wide or in large targeted panels. We applied it to ventricular cerebrospinal fluid (CSF) and could determine the turnover parameters of almost 200 proteins, whereas a handful were known previously. We covered a large number of neuron biology- and immune system-related proteins including many biomarkers and drug targets. This first large data set unraveled a significant relationship between turnover and protein origin that relates to our ability to investigate the central nervous system physiology precisely in future studies. Our data constitute a reference in CSF biology as well as a repertoire of peptides for the community to design new proteome dynamics analyses. The disclosed methods apply to other fluids or tissues provided sequential sample collection can be performed.

[1]  Lindsay K. Pino,et al.  The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. , 2020, Mass spectrometry reviews.

[2]  Monocyte Differentiation Antigen CD14 , 2020, Definitions.

[3]  Martin Eisenacher,et al.  Characterization of Cerebrospinal Fluid via Data-Independent Acquisition Mass Spectrometry. , 2018, Journal of proteome research.

[4]  P. Lescuyer,et al.  Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods , 2018, Critical reviews in clinical laboratory sciences.

[5]  R. Bateman,et al.  Erratum: Tau Kinetics in Neurons and the Human Central Nervous System (Neuron (2018) 97(6) (1284–1298.e7)(S0896627318301363)(10.1016/j.neuron.2018.02.015)) , 2018 .

[6]  R. Bateman,et al.  Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.

[7]  J. Iliff,et al.  The Emerging Relationship Between Interstitial Fluid–Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep , 2018, Biological Psychiatry.

[8]  Birgit Schilling,et al.  Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques , 2017, Expert review of proteomics.

[9]  R. Sadygov,et al.  Gaussian Process Modeling of Protein Turnover. , 2016, Journal of proteome research.

[10]  R. Beynon,et al.  Proteome Dynamics: Tissue Variation in the Kinetics of Proteostasis in Intact Animals* , 2016, Molecular & Cellular Proteomics.

[11]  A. Labarga,et al.  Toward defining the anatomo‐proteomic puzzle of the human brain: An integrative analysis , 2015, Proteomics. Clinical applications.

[12]  L. Bernstein,et al.  Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States , 2015, Advances in nutrition.

[13]  R. Bateman,et al.  In vivo kinetic approach reveals slow SOD1 turnover in the CNS. , 2015, The Journal of clinical investigation.

[14]  Brian J. Bleakley,et al.  Abstract 353: Characterization Of Human Plasma Proteome Dynamics Using Deuterium Oxide , 2014 .

[15]  Edward Lau,et al.  Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. , 2014, The Journal of clinical investigation.

[16]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[17]  Christoph H Borchers,et al.  Method and platform standardization in MRM-based quantitative plasma proteomics. , 2013, Journal of proteomics.

[18]  Aditi Chatterjee,et al.  Plasma Proteome Database as a resource for proteomics research: 2014 update , 2013, Nucleic Acids Res..

[19]  H. Zou,et al.  A six-plex proteome quantification strategy reveals the dynamics of protein turnover , 2013, Scientific Reports.

[20]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[21]  M. Krüger,et al.  Stable Isotope Labeling in Zebrafish Allows in Vivo Monitoring of Cardiac Morphogenesis* , 2013, Molecular & Cellular Proteomics.

[22]  R. Beynon,et al.  Proteome Dynamics: Revisiting Turnover with a Global Perspective* , 2012, Molecular & Cellular Proteomics.

[23]  Iain S. Young,et al.  A proteomics strategy for determining the synthesis and degradation rates of individual proteins in fish. , 2012, Journal of proteomics.

[24]  Norman E. Davey,et al.  Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins , 2012, Cell.

[25]  D. Holtzman,et al.  In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS , 2012, PloS one.

[26]  S. Guan,et al.  Compartment modeling for mammalian protein turnover studies by stable isotope metabolic labeling. , 2012, Analytical chemistry.

[27]  M. Doherty,et al.  Proteomics moves from expression to turnover: update and future perspective , 2011, Expert review of proteomics.

[28]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[29]  S. Guan,et al.  Analysis of proteome dynamics in the mouse brain , 2010, Proceedings of the National Academy of Sciences.

[30]  K. Nair,et al.  Impact of type 1 diabetes and insulin treatment on plasma levels and fractional synthesis rate of retinol-binding protein 4. , 2009, The Journal of clinical endocrinology and metabolism.

[31]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[32]  Sylvain Lehmann,et al.  Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers , 2008, Proteomics. Clinical applications.

[33]  E. Tsilibary,et al.  Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP , 2007, Neurobiology of Disease.

[34]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[35]  K. Nair,et al.  In vivo measurement of synthesis rate of multiple plasma proteins in humans. , 2006, American journal of physiology. Endocrinology and metabolism.

[36]  R. Veerhuis,et al.  Microglia kill amyloid-&bgr;1-42 damaged neurons by a CD14-dependent process , 2004, NeuroReport.

[37]  J. C. Price,et al.  Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. , 2012, Analytical biochemistry.

[38]  Anna Kinsey,et al.  Plasma transthyretin as a candidate marker for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[39]  J. Waterlow Whole-body protein turnover in humans--past, present, and future. , 1995, Annual review of nutrition.